DELAYED: Postmarketing obligations hang up Orexigen obesity drug
This article was originally published in Scrip
Executive Summary
Shares of Orexigen tumbled about 20% in morning trading on 11 June after the company revealed the FDA had imposed a three-month delay on its verdict on whether it will permit the firm's antiobesity drug to NB32 (naltrexone SR/bupropion SR), better known as Contrave, to enter the US market.